Literature DB >> 31646277

Diagnostic challenges in supraventricular tachycardia: anticipating value of natriuretic peptides.

Ertan Yetkin1.   

Abstract

It is important not to overlook supraventricular tachycardia (SVT) in patients complaining of palpitation or tachycardia-related symptoms but with normal ECG and heart rate in emergency department or outpatient clinics. The severity and presentation of symptoms is highly variable and depends on features including heart rate, duration of tachycardia, underlying heart disease, and individual patient perception. Early measurement of natriuretic peptides in patients presenting with palpitation and/or tachycardia-related symptoms would guide the clinician to rule out tachycardia and/or SVT. High levels of natriuretic peptides within 30 min of postattack period would certainly increase the likelihood of SVT.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Keywords:  C-type natriuretic peptide; atrial natriuretic peptide; brain natriuretic peptide; natriuretic peptides; supraventricular tachycardia

Year:  2018        PMID: 31646277      PMCID: PMC6739847          DOI: 10.1097/XCE.0000000000000148

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol Metab        ISSN: 2574-0954


  34 in total

1.  Cardiology patient pages. Supraventricular tachycardia.

Authors:  Paul J Wang; N A Mark Estes
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Documented but non-induced supraventricular tachycardia and vice versa.

Authors:  Ertan Yetkin
Journal:  Int J Cardiol       Date:  2015-01-03       Impact factor: 4.164

3.  Atrial natriuretic peptide during supraventricular tachycardia and relation to hemodynamic changes and renal function.

Authors:  R C Tsai; T Yamaji; M Ishibashi; F Takaku; S C Pang; S J Yeh; Y S Lee; J S Hung; D Wu
Journal:  Am J Cardiol       Date:  1988-06-01       Impact factor: 2.778

4.  Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs.

Authors:  T Maack; D N Marion; M J Camargo; H D Kleinert; J H Laragh; E D Vaughan; S A Atlas
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

5.  Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers.

Authors:  I Tikkanen; F Fyhrquist; K Metsärinne; R Leidenius
Journal:  Lancet       Date:  1985-07-13       Impact factor: 79.321

6.  Responses of cardiac natriuretic peptides after paroxysmal supraventricular tachycardia: ANP surges faster than BNP and CNP.

Authors:  Jen-Yuan Kuo; An-Mei Wang; Sheng-Hsiung Chang; Chung-Lieh Hung; Chun-Yen Chen; Bing-Fu Shih; Hung-I Yeh
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-22       Impact factor: 4.733

Review 7.  Natriuretic peptide system and the heart.

Authors:  Silvia Del Ry; Manuela Cabiati; Aldo Clerico
Journal:  Front Horm Res       Date:  2014-06-10       Impact factor: 2.606

8.  Effect of induced supraventricular tachycardias on changes in urine output and plasma hormone levels in man.

Authors:  G C Kaye; P Bayliss; P J Lowry; P L Drury; A J Camm
Journal:  Clin Sci (Lond)       Date:  1992-01       Impact factor: 6.124

9.  Plasma levels of immunoreactive atrial natriuretic factor increase during supraventricular tachycardia.

Authors:  J M Nicklas; L A DiCarlo; P T Koller; F Morady; E A Diltz; Y Shenker; R J Grekin
Journal:  Am Heart J       Date:  1986-11       Impact factor: 4.749

10.  Asthma-like attacks terminated by slow pathway ablation.

Authors:  Selcuk Ozturk; Hasan Turhan; Ertan Yetkin
Journal:  Ann Thorac Med       Date:  2017 Apr-Jun       Impact factor: 2.219

View more
  1 in total

1.  Clinical presentation of paroxysmal supraventricular tachycardia: evaluation of usual and unusual symptoms.

Authors:  Ertan Yetkin; Selcuk Ozturk; Bilal Cuglan; Hasan Turhan
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-05-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.